* those who are using immunosuppressive drugs or long-term immunosuppressive drugs after organ transplantation. * t lymphocyte abnormality (allogeneic may be considered, depending on clinical opinion), hiv positive. * highly allergic or have a history of severe allergy, especially interleukin-2 allergy. * pregnant and lactating women. * patients with severe autoimmune disease history; allergies to all biological reagents in this treatment, such as interleukin-2. * patients with serious complications, including chronic cardiac insufficiency (nyha cardiac function grading assessment of cardiac function grade iii - iv), chronic renal insufficiency (ckd stage 3 and above); chronic liver insufficiency (child-pugh score\>7); patients with malignant tumors. * patients with pulmonary embolism or acute coronary syndrome. * patients with severe organ dysfunction caused by other diseases. * there are other situations that the researcher thinks are not suitable to participate in this clinical study

* those who are using immunosuppressive drugs or long-term immunosuppressive drugs after organ transplantation. * t lymphocyte abnormality (allogeneic may be considered, depending on clinical opinion), hiv positive. * highly allergic or have a history of severe allergy, especially interleukin-2 allergy. * pregnant and lactating women. * patients with severe autoimmune disease history; allergies to all biological reagents in this treatment, such as interleukin-2. * patients with serious complications, including chronic cardiac insufficiency (nyha cardiac function grading assessment of cardiac function grade iii - iv), chronic renal insufficiency (ckd stage 3 and above); chronic liver insufficiency (child-pugh score\>7); patients with malignant tumors. * patients with pulmonary embolism or acute coronary syndrome. * patients with severe organ dysfunction caused by other diseases. * there are other situations that the researcher thinks are not suitable to participate in this clinical study

those who are using immunosuppressive drugs or long-term immunosuppressive drugs after organ transplantation. t lymphocyte abnormality (allogeneic may be considered, depending on clinical opinion), hiv positive. highly allergic or have a history of severe allergy, especially interleukin-2 allergy. pregnant and lactating women. patients with severe autoimmune disease history; allergies to all biological reagents in this treatment, such as interleukin-2. patients with serious complications, including chronic cardiac insufficiency (nyha cardiac function grading assessment of cardiac function grade iii - iv), chronic renal insufficiency (ckd stage 3 and above); chronic liver insufficiency (child-pugh score>7); patients with malignant tumors. patients with pulmonary embolism or acute coronary syndrome. patients with severe organ dysfunction caused by other diseases. there are other situations that the researcher thinks are not suitable to participate in this clinical study

those who are using immunosuppressive drugs or long-term immunosuppressive drugs after organ transplantation. t lymphocyte abnormality (allogeneic may be considered, depending on clinical opinion), hiv positive. highly allergic or have a history of severe allergy, especially interleukin-2 allergy. pregnant and lactating women. patients with severe autoimmune disease history; allergies to all biological reagents in this treatment, such as interleukin-2. patients with serious complications, including chronic cardiac insufficiency (nyha cardiac function grading assessment of cardiac function grade iii - iv), chronic renal insufficiency (ckd stage 3 and above); chronic liver insufficiency (child-pugh score>7); patients with malignant tumors. patients with pulmonary embolism or acute coronary syndrome. patients with severe organ dysfunction caused by other diseases. there are other situations that the researcher thinks are not suitable to participate in this clinical study